

1 **Efficacy of remdesivir-containing therapy in hospitalized COVID-19**
2 **patients: a prospective clinical experience**

3

4

5 Alessandro Russo¹, Erica Binetti², Cristian Borrazzo², Elio Gentilini Cacciola², Luigi Battistini²,
6 Giancarlo Ceccarelli², Claudio Maria Mastroianni², Gabriella d'Ettore²

7

8 ¹ Infectious and Tropical Disease Unit, Department of Medical and Surgical Sciences, "Magna Graecia"
9 University of Catanzaro, Italy

10 ² Policlinico "Umberto I", Department of Public Health and Infectious Diseases, "Sapienza" University of Rome,
11 Italy

12

13

14 **Running head:** Remdesivir for treatment of COVID-19

15

16 **Word count:** 2201

17

18

19

20

21

22

23

24

25 **Corresponding author**

26 Prof. Alessandro Russo

27 Infectious and Tropical Disease Unit, Department of Medical and Surgical Sciences

28 Viale Europa, 88100, "Magna Graecia" University of Catanzaro, Italy

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

29 Email: a.russo@unicz.it; alessandro.russo1982@gmail.com

30 **ABSTRACT**

31 **Objectives:** remdesivir is currently approved for the treatment of COVID-19. The recommendation
32 for using remdesivir in COVID-19 was based on the *in vitro* and *in vivo* activity of this drug against
33 SARS-CoV-2.

34 **Methods:** this was a prospective, observational study conducted on a large population of patients
35 hospitalized for COVID-19. The primary endpoint of the study was to evaluate the impact of
36 remdesivir-containing therapy on 30-day mortality; secondary endpoint was the impact of
37 remdesivir-containing therapy on the need of high flow oxygen therapy (HFNC) or non-invasive
38 ventilation (NIV) or mechanical ventilation. Data were analyzed after propensity score matching.

39 **Results:** 407 patients with SARS-CoV-2 pneumonia were consecutively enrolled. Out of these, 294
40 (72.2%) and 113 (27.8%) were respectively treated or not with remdesivir. Overall, 61 (14.9%)
41 patients were treated during hospitalization with non-invasive or mechanical ventilation, while a 30-
42 day mortality was observed in 21 (5.2%) patients with a global in-hospital mortality of 11%. Cox
43 regression analysis, after propensity score matching, showed that therapies, including remdesivir-
44 containing therapy, were not statistically associated with 30-day survival or mortality, while need of
45 HFNC/NIV (HR 17.921, CI95% 0.954-336.73, p=0.044) and mechanical ventilation (HR 3.9,
46 CI95% 5.36-16.2, p=0.003) resulted independently associated with 30-day mortality. Finally,
47 therapies including or not remdesivir were not independently associated with a lower or higher risk
48 of HFNC/NIV or mechanical ventilation.

49 **Conclusions:** this real-life experience about the remdesivir use in hospitalized patients with
50 COVID-19 was not associated with significant increase in rates of survival or reduced use of
51 HFNC/NIV or mechanical ventilation, compared to patients treated with other therapies not
52 including remdesivir.

53

54 **Key words:** remdesivir; COVID-19; pneumonia; non-invasive ventilation; mechanical ventilation.

55

56

57 INTRODUCTION

58 Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is identified as the cause
59 of an outbreak of respiratory illness, evolving in a pandemic. The virus causes respiratory illness
60 and can rapidly spread from person to person; then, in a large number of patients this virus causes
61 coronavirus diseases (COVID-19) characterized by pneumonia, severe acute respiratory syndrome,
62 kidney failure, and a significant rate of mortality [1-2-3].

63 To date, treatment of critically ill infected patients is primarily supportive with a robust
64 evidence reported in literature about the use of steroids, especially dexamethasone, in lowering
65 mortality especially in critically ill patients [4]; some important evidence suggests also the role of
66 low-molecular-weight heparin (LMWH) to reduce in-hospital mortality [5].

67 As a matter of fact, only remdesivir was currently approved for the treatment of COVID-19.
68 The recommendation for using remdesivir as treatment of COVID-19 is based on the *in vitro* and *in*
69 *vivo* activity of remdesivir against SARS-CoV-2 [6]. Moreover, remdesivir showed an acceptable
70 safety profile and exhibits *in vivo* prophylactic and therapeutic efficacy against SARS-CoV-2
71 infection [7].

72 According to randomized clinical trials, its administration might shorten the time to
73 recovery and reduce severity of infection in adults hospitalized with COVID-19 [8]. However, there
74 are still many ongoing clinical trials and more evidence is needed to confirm the efficacy of
75 remdesivir in treating patients with COVID-19 at different stages of severity.

76 Aim of our study was to evaluate in a real-life, prospective, experience the impact of
77 remdesivir on 30-day mortality and the need of non-invasive or invasive ventilation in hospitalized
78 patients with SARS-CoV-2 pneumonia.

79

80

81

82

83

84 **RESULTS**

85 During the study period 407 patients with SARS-CoV-2 pneumonia were consecutively
86 enrolled. Out of these, 294 (72.2%) and 113 (27.8%) were respectively treated or not with
87 remdesivir. Overall, 61 (14.9%) patients were treated during hospitalization with non-invasive or
88 mechanical ventilation, while a 30-day mortality was observed in 21 (5.2%) patients, with a global
89 in-hospital mortality of 11%.

90 In **Table 1** is reported univariate analysis about demographics and clinical characteristics of
91 COVID-19 patients treated or not with remdesivir. Statistically significant differences were
92 observed in remdesivir group about male sex (80% Vs 62%, $p<0.001$), fever (79% Vs 50%,
93 $p<0.001$), cough (50% Vs 29%, $p<0.001$), dyspnea (57% Vs 37%, $p<0.001$), compared to patients
94 not treated with remdesivir. No statistically significant differences were observed in the remdesivir
95 group about age (63.2 Vs 62.5 years, $p=0.717$), length of hospital stay (15.02 Vs 16.06 days,
96 $p=0.487$), and days to nasopharyngeal swab negativization (22.07 vs 24.77 days, $p=0.378$). Finally,
97 no differences were observed about bacterial co-infection (20% Vs 21%, $p=0.928$) and 30-day
98 mortality (4% Vs 6%, $p=0.411$).

99 Other treatments used in COVID-19 patients were reported in **Table 2**. Comparison between
100 patients treated or not with remdesivir showed that steroids (93% Vs 81%, $p<0.001$), LMWH (93%
101 Vs 52%, $p<0.001$) were more frequently prescribed in remdesivir group. Antibiotic therapy (58%
102 Vs 27%, $p<0.001$) was more frequently prescribed for patients not treated with remdesivir, while no
103 differences were reported about the use of HFNC/NIV or mechanical ventilation in the 2 study
104 groups.

105 In **supplementary Table 1** is reported univariate analysis after propensity score matching to
106 evaluate the impact of remdesivir-containing regimen on study population (**for reviewers'**
107 **information only**). **Figure 1** showed Kaplan Meier curves about 30-day survival in patients treated

108 or not with remdesivir before ($p=0.24$) and after ($p=0.07$) propensity score matching, reporting no
109 differences between the 2 study groups. Standardized differences before and after propensity score
110 matching were reported in **supplementary Figure 1 (for reviewers' information only)**.

111 Multivariate Cox regression analysis about 30-day mortality after propensity score matching
112 was reported in **Table 3**. Comorbidities and therapies, including remdesivir-containing therapy,
113 were not statistically associated with 30-day survival or mortality. Instead, HFNC/NIV (HR 17.921,
114 CI95% 0.954-336.73, $p=0.044$) and mechanical ventilation (HR 3.9, CI95% 5.36-16.2, $p=0.003$)
115 resulted independently associated with 30-day mortality

116 Finally, multivariate Cox regression analysis about need of non-invasive or invasive
117 ventilation was analyzed after propensity score matching (see **Table 4**). Data showed that
118 comorbidities and therapies, including remdesivir-containing regimen, were not independently
119 associated with a lower or higher risk of HFNC/NIV or mechanical ventilation.

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135 **DISCUSSION**

136 This prospective clinical study reported a real-life experience about the use of remdesivir in
137 a large population of consecutively hospitalized patients with COVID-19. Our data, also after
138 propensity score matching, showed that remdesivir-containing regimen was not associated with 30-
139 day survival compared to patients treated with other therapies not including remdesivir. Moreover,
140 remdesivir-containing regimen was not independently related to progression or not to HFNC/NIV
141 or mechanical ventilation.

142 In Italy, remdesivir was specifically licensed for the treatment of COVID-19 in hospitalized
143 patients with pneumonia, requiring oxygen therapy but not treated with HFNC/NIV or mechanical
144 ventilation at time of remdesivir prescription [9].

145 Different data were worldwide reported about the efficacy of remdesivir, taking in account
146 different outcomes. Remdesivir treatment was associated with significantly higher recovery rates
147 and lower mortality, compared to standard-of-care treatment without remdesivir in patients with
148 severe COVID-19 [10]. In this study, significantly lower mortality was observed in those treated
149 with remdesivir (7.6%) compared with the non-remdesivir-cohort patients (12.5%). Conversely,
150 data from Solidarity trial, conducted in 30 countries [11], showed no decrease of in-hospital
151 mortality in patients treated with remdesivir, with the important limitation that other outcomes,
152 clinical improvement and adverse events, were non carefully evaluated.

153 Some important meta-analysis showed that COVID-19 patients receiving remdesivir had
154 significantly higher rates of recovery and hospital discharge with lower rates of developing serious
155 adverse events compared to patients receiving standard of care/placebo [12-13]. However, these
156 analyses confirmed that no significant differences were observed about clinical improvement and
157 rate of mortality during hospitalization. Specifically, mortality was the main outcome reported in all
158 included studies, and none of the studies showed significant decrease of mortality also if they were
159 not adequately powered for mortality outcome [12].

160 Wang et al. [14] reported the first double blinded, randomized, clinical trial in which were
161 evaluated patients with an interval from symptoms onset to enrollment of 12 days or less. No
162 differences in mortality were recorded in the 2 arms, also if authors highlighted a possible trend
163 towards clinical benefit in remdesivir group. Of importance, a large number of patients in this study
164 were treated also with steroids (65% of patients who received remdesivir and 68% of patients in
165 placebo arm) which may have confounded the results and the conclusions. A strength of our study,
166 with the limit of the non-randomized cohort, was to weight all the possible therapeutic confounders,
167 comprising the use of steroids and LMWH.

168 Beigel et al. [8] randomized 1062 patients, hospitalized with COVID-19 and evidence of
169 pneumonia, to remdesivir or placebo. The study demonstrated that remdesivir was superior to
170 placebo in shortening the time to recovery in hospitalized COVID-19 patients with a trend towards
171 survival benefit at day 29 without statistically significant differences. Of interest, authors reported a
172 beneficial effect of remdesivir in severe COVID-19 patients but not requiring mechanical
173 ventilation at enrollment; they suggested to start remdesivir early in the disease course.

174 Finally, in another randomized, clinical trial [15] in patients with moderate COVID-19 (no
175 oxygen requirements, also if about 15% of patients required oxygen at time of enrollment) authors
176 randomized 596 patients in 1:1:1 ratio to receive a 5-day course of remdesivir, a 10- day course of
177 remdesivir, or standard of care therapy. In this study patients randomized to 5-day, but not 10- day
178 treatment duration, showed a statistically significant difference in clinical status. A subgroup
179 analysis excluding patients who required oxygen at baseline showed a significant difference
180 favouring remdesivir over standard care.

181 Our study has some limitations. First, considering the monocentric design these results
182 might be affected by local practice in the management of COVID-19; second, although criteria for
183 HFNC/NIV or mechanical ventilation were based on the degree of respiratory impairment, elderly
184 critically ill patients with ultimately fatal diseases were probably excluded from non-
185 invasive/invasive ventilation, modifying the interpretation of some interventions. Second, in this

186 analysis were evaluated all consecutively, hospitalized patients independently from COVID-19
187 severity, as demonstrated also by the low mortality (6% of remdesivir group Vs 4% of patients not
188 treated with remdesivir). Finally, the analysis on the beneficial effects of treatments should be
189 interpreted cautiously, because it was not conducted on randomized groups and might therefore be
190 affected by several measured and unmeasured confounding factors. However, the comparison of
191 remdesivir-treated patients with non-remdesivir-treated patients was based on a robust statistical
192 methodology, appropriate for non-randomized cohort studies about therapy.

193 In conclusion, in our real-life experience about the remdesivir use in hospitalized patients
194 with COVID-19 was not associated with significant increase in rates of survival or reduced use of
195 HFNC/NIV or mechanical ventilation, compared to patients treated with other therapies not
196 including remdesivir. These results suggest the need of more RCTs to evaluate the role of
197 remdesivir in COVID-19 patients at different stages of disease or in combination with other drugs
198 [16]. However, considering its safety profile and the lack of alternative drugs, remdesivir should be
199 continued to be administered for patients with COVID-19.

200

201

202

203

204

205

206

207

208

209

210

211

212 **METHODS**

213 *Study Design and Data Collection*

214 This prospective, observational study included, from October 2020 to February 2021,
215 patients admitted to University Hospital of Rome ‘‘Policlinico Umberto I’’, in Italy. Inclusion
216 criteria were: 1) positive SARS-CoV-2 real-time polymerase chain reaction test or an antigenic test
217 on a nasopharyngeal swab; 2) pneumonia diagnosed either by CT thorax or chest x-ray; 3) need of
218 hospitalization. Patients who required high flow oxygen therapy (HFNC) or non-invasive
219 ventilation (NIV) or mechanical ventilation at time of hospitalization were excluded from this
220 analysis.

221 All patients were evaluated in a dedicated Emergency Department by a dedicated staff of
222 infectious diseases specialists that identified patients with SARS-CoV-2 pneumonia as soon as they
223 arrived at the hospital, followed the patients during the hospital stay, and collected all data
224 prospectively without interfering with the therapeutic decisions. This observational study was
225 conducted according to the principles stated in the Declaration of Helsinki, and it conforms to
226 standards currently applied in our country. The study was approved by the local EC. The patient’s
227 informed consent was obtained.

228 Data were extracted from the medical records of patients and from hospital computerized
229 databases. The following data were collected: demographics, clinical and laboratory findings,
230 comorbidities, Charlson comorbidity index, microbiologic data, date of COVID-19 diagnosis,
231 radiological characteristics of the pneumonia, therapies, concomitant infections, duration of
232 mechanical ventilation, time of nasopharyngeal swab negativity, need of oxygen or ventilation
233 support during the hospital stay, length of ICU stay, length of hospital stay. Development of
234 moderate to severe ARDS was defined as the acute onset of hypoxemia, manifestations of
235 pneumonia on chest computed tomography imaging of a noncardiac origin, and a PaO₂/FiO₂ ratio
236 of less than 200 mmHg according to the Berlin Definition [17].

237 Remdesivir was administrated, after written informed consent, to patients with the following
238 characteristics: pneumonia, less than 10 days from the onset of symptoms, no need for HFNC or
239 NIV or mechanical ventilation, alanine aminotransferase no more than 5 times the upper limit of the
240 reference range, estimated glomerular filtration rate (eGFR) greater than 30 mL/minute. A 5-day
241 regimen was prescribed in all cases. Patients without these criteria were not eligible for remdesivir
242 treatment.

243 All patients were followed-up until discharge or death.

244

245 **Endpoints and Statistical analysis**

246 The primary endpoint of the study was to evaluate the impact of remdesivir-containing
247 therapy on 30-day mortality in hospitalized patients with SARS-CoV2 pneumonia. Secondary
248 endpoint was the impact of remdesivir-containing therapy on the need of NIV or mechanical
249 ventilation.

250 To reduce the impact of treatment-selection bias in the estimation of treatment effects,
251 propensity score matching was conducted. Variables were selected for inclusion in the propensity
252 score based on potential impact on receipt of remdesivir and association with mortality [18]. The
253 variables included were steroids, antibiotics (excluding macrolides), age, gender, and the use of
254 LMWH during hospital admission. A propensity score density plot and Love plot were generated to
255 examine the balance of propensity score and covariate distribution between the two groups (see
256 **supplementary Figure 1**).

257 To evaluate demographic factors, Welch's t tests assuming unequal variances were used for
258 continuous independent variables, while Pearson Chi-square or Fisher's Exact Test when
259 appropriate were used for categorical variables. Welch's analysis of variance (ANOVA) was used
260 to assess group differences for continuous outcome. Welch's t-tests assuming unequal variances
261 were used for post-hoc comparisons.

262 All tests will be two-tailed, and a p-value of <0.05 were considered statistically significant.
263 Results were expressed as the mean with standard deviation (\pm SD) for continuous normally
264 distributed variables and as a count (n) and percentage (%) for categorical variables. Multivariate
265 analysis was used to identify independent predictors of 30-day mortality and need of NIV or
266 mechanical ventilation. Matched bivariate analyses were conducted using a conditional logistic
267 regression model, incorporating all variables found to be significant in the Univariate analysis ($p <$
268 0.05) with a stepwise method. Matched multivariate models was constructed using Cox
269 proportional hazards (HRs) regression if appropriate, accounting for clustering on matched pairs.
270 The final selected model was tested for confounding. In addition, 95% confidence intervals were
271 calculated for HR. Survival was analyzed by Kaplan-Meier curves. All data were analyzed using a
272 commercially available statistical software package (SPSS Statistics for Mac, 22.0; IBM Corp.,
273 Armonk, NY).

274

275

276

277 **ACKNOWLEDGEMENT**

278 **Conflict of interest:** none to declare.

279 **Funding:** none.

280 **Transparency declarations:** none to declare.

281

282

283

284

285

286

287

288

289

290

291

292
293
294
295
296
297
298
299
300

Table 1. Univariate analysis about demographics and clinical characteristics of COVID-19 patients treated or not with remdesivir

Variables	No remdesivir N = 113 (%)	Remdesivir N = 294 (%)	P value
Male sex	70 (62%)	250 (80%)	<0.001
Age, year, mean (± SD)	62.5 (± 20)	63.2 (± 15.3)	0.717
Days from symptoms/positive nasopharyngeal swab to admission, mean (± SD)	4.5 (± 4.3)	5.3 (± 3.8)	0.084
Comorbidities	77 (68%)	213 (70%)	0.919
Cardiovascular disease	17 (15%)	33 (11%)	0.203
COPD	19 (17%)	31 (10%)	0.051
Chronic kidney disease	10 (9%)	18 (6%)	0.256
Liver cirrhosis	2 (2%)	12 (4%)	0.293
Diabetes mellitus	21 (19%)	53 (17%)	0.672
Solid lung cancer (primary or metastasis)	1 (1%)	3 (1%)	1.000
Fever	56 (50%)	246 (79%)	<0.001
Cough	33 (29%)	157 (50%)	<0.001
Dyspnea	42 (37%)	178 (57%)	<0.001
Gastrointestinal symptoms (diarrhea, abdominal discomfort, nausea, vomiting)	16 (14%)	58 (18%)	0.271
Fatigue	21 (19%)	57 (19%)	1.000
Pharyngodynia	6 (5%)	14 (5%)	1.000
Rhinitis	3 (3%)	15 (5%)	0.329
Arthralgia/Myalgia	13 (12%)	45 (14%)	0.460
Anosmia	3 (3%)	9 (3%)	1.000

Variables	No remdesivir N = 113 (%)	Remdesivir N = 294 (%)	P value
Conjunctivitis	0 (0%)	2 (1%)	0.397
Chest pain	5 (4%)	11 (3%)	0.655
Signs of overload (limb edema and/or pulmonary stasis)	4 (4%)	2 (1%)	0.647
Parenchymal thickening	72 (64%)	232 (74%)	0.046
Interstitial lung disease	16 (14%)	15 (5%)	<0.001
Pleural effusion	20 (18%)	26 (9%)	0.012
Cardiomegaly	8 (7%)	16 (5%)	0.438
Bronchiectasis/ Emphysema	27 (24%)	50 (15%)	0.032
White Blood cells x10 ³ /uL, mean (±SD)	7.38 (± 3.59)	8.06 (± 5.99)	0.287
Neutrophils x10 ³ /uL, mean (±SD)	5.60 (± 3.61)	6.31 (± 5.31)	0.211
Lymphocytes x10 ³ /uL, mean (±SD)	1.18 (± 0.65)	1.12 (± 2.28)	0.769
Platelets x10 ³ /uL, mean (±SD)	247.66 (± 100.85)	218.47 (± 81.73)	0.004
D-dimer ng/mL, mean (±SD)	1365.71 (± 1456.18)	814.91 (± 766.45)	<0.001
Ferritin ng/mL, mean (±SD)	692.35 (± 942.17)	645.02 (± 489.52)	0.591
Procalcitonin ng/mL, mean (±SD)	1.20 (± 6.4)	0.61 (± 3.73)	0.334
LDH mU/mL, mean (±SD)	288.46 (± 163.73)	302.37 (± 119.57)	0.3
CPK U/L, mean (±SD)	278.90 (± 1430.63)	149.47 (± 161.35)	0.170
Lactates mmol/L, mean (±SD)	1.57 (± 0.36)	1.33 (± 0.83)	0.328
C-reactive protein mg/dL, mean (±SD)	4.91 (± 6.61)	8.23 (± 21.13)	0.116
PaO ₂ /FiO ₂ , mean (±SD)	315.67 (± 117.14)	329.94 (± 98.36)	0.411
Aspartate Transaminase U/L, mean (±SD)	34.16 (± 47.76)	35.24 (± 27.41)	0.784
Alanine transaminase U/L, mean (±SD)	32.20 (± 28.42)	33.24 (± 28.84)	0.755
Bacterial co-infection	24 (21%)	65 (20%)	0.928
Days of hospitalization, mean (±SD)	16.06 (± 17.62)	15.02 (± 9.98)	0.487
Days to nasopharyngeal swab negativization, mean (±SD)	24.77 (± 17.1)	22.07 (± 13.77)	0.378
30-day mortality	4 (4%)	17 (6%)	0.411

Legend. COPD: chronic obstructive pulmonary disease; LDH: lactate dehydrogenase; CPK: ; creatine phosphokinase.

304
305
306
307
308
309
310
311
312

313 **Table 2.** Other treatments in COVID-19 patients treated or not with remdesivir

Variables	No remdesivir N = 113 (%)	Remdesivir N = 294 (%)	P value
Steroids	92 (81%)	289 (93%)	<0.001
Antibiotics (excluding macrolides)	65 (58%)	83 (27%)	<0.001
Macrolides	74 (65%)	146 (46%)	<0.001
Low-molecular-weight heparin	59 (52%)	280 (93%)	<0.001
Low-flow oxygen therapy / no need of oxygen therapy	89 (79%)	275 (87%)	0.044
HFNC/NIV	17 (15%)	33 (10%)	0.155
Mechanical ventilation	1 (1%)	10 (3%)	0.2

314 **Legend.** HFNC: high flow nasal cannula; NIV: non-invasive ventilation.

315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339

340
341
342
343
344
345
346
347
348
349
350

Table 3. Multivariate Cox regression analysis about 30-day mortality after propensity score matching

Variables	HR	CI95%	P value
Comorbidities	0.136	0.009-2.04	0.149
Chronic kidney disease	1.773	0.022-140.18	0.797
COPD	3.033	0.097-95.03	0.528
Bacterial co-infection	0.693	0.061-7.81	0.767
Low-molecular-weight heparin	0.169	0.013-2.17	0.173
Macrolides	23.056	0.273-19,8	0.165
Antibiotics (excluding macrolides)	1.512	0.18-12.67	0.703
Steroids	0.1	0.0-1.2	0.89
Low-flow oxygen therapy/no need of oxygen therapy	11.682	0.575-237.45	0.11
Remdesivir	0.87	0.12-1.17	0.18
HFNC/NIV	17.921	0.954-336.73	0.044
Mechanical ventilation	3.9	5.36-16.2	0.003

351 **Legend.** COPD: chronic obstructive pulmonary disease; HFNC: high flow nasal cannula; NIV: non-invasive
352 ventilation.

353
354
355
356
357
358
359
360
361
362
363
364
365
366

367
368
369
370
371
372
373
374
375
376
377

Table 4. Multivariate Cox regression analysis about need of non-invasive or invasive ventilation after propensity score matching

Variables	HR	IC	P value
Comorbidities	0.1	0.09-1.4	0.149
Chronic kidney disease	1.8	0.24-4.2	0.797
COPD	1.03	0.068-15.64	0.528
Bacterial co-infection	0.7	0.1-1.81	0.767
Low-molecular-weight heparin	0.169	0.01-2.17	0.173
Macrolides	0.31	0.01-8.8	0.493
Antibiotics (excluding Macrolides)	1.51	0.18-12.67	0.703
Steroids	3.2	0.78-136.9	0.890
Remdesivir	1.03	0.68-15.6	0.737

378 **Legend.** COPD: chronic obstructive pulmonary disease.

379
380

381

382

383

384

385

386

387

388

389


390

391

392 **Figure 1.** Kaplan Meier curves about 30-day survival in patients treated or not with remdesivir
393 before ($p=0.24$) and after ($p=0.07$) propensity score matching

394

395



396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413 **REFERENCES**

¹ <https://covid19.who.int>, Accessed on 27 April 2021.

² Russo A, Bellelli V, Ceccarelli G, Marincola Cattaneo F, Bianchi L, Pierro R, Russo R, Steffanina A, Pugliese F, Mastroianni CM, d'Ettore G, Sabetta F. 2020. Comparison between hospitalized patients affected or not by COVID-19 (RESILIENCY study). *Clin Infect Dis*. 2020 Nov 18:ciaa1745. doi: 10.1093/cid/ciaa1745. Epub ahead of print.

³ Vistoli F, Furian L, Maggiore U, Caldara R, Cantaluppi V, Ferraresso M, Zaza G, Cardillo M, Biancofiore G, Menichetti F, Russo A, Turillazzi E, Di Paolo M, Grandaliano G, Boggi U; Italian National Kidney Transplantation Network; the Joint Committee of the Italian Society of Organ Transplantation and the Italian Society of Nephrology. 2020. COVID-19 and kidney transplantation: an Italian Survey and Consensus. *J Nephrol*. 33:667-680.

⁴ RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ. 2021. Dexamethasone in Hospitalized Patients with Covid-19. *N Engl J Med*. 384:693-704.

⁵ Falcone M, Tiseo G, Barbieri G, Galfo V, Russo A, Viridis A, Forfori F, Corradi F, Guarracino F, Carrozzi L, Celi A, Santini M, Monzani F, De Marco S, Pistello M, Danesi R, Ghiadoni L, Farcomeni A, Menichetti F; Pisa COVID-19 Study Group. 2020. Role of Low-Molecular-Weight Heparin in Hospitalized Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia: A Prospective Observational Study. *Open Forum Infect Dis*. 7:ofaa563

⁶ Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. 2020. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res*. 30:269-271.

⁷ Frediansyah A, Nainu F, Dhama K, Mudatsir M, Harapan H. Remdesivir and its antiviral activity against COVID-19: A systematic review. *Clin Epidemiol Glob Health*. 2021;9:123-127.

⁸ Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC; ACTT-1 Study Group Members. 2020. Remdesivir for the Treatment of Covid-19 - Final Report. *N Engl J Med*. 383:1813-1826.

⁹ <https://www.aifa.gov.it/-/procedura-di-richiesta-per-il-farmaco-veklury-remdesivir>. Accessed on 28 April 2021.

¹⁰ Olender SA, Perez KK, Go AS, Balani B, Price-Haywood EG, Shah NS, Wang S, Walunas TL, Swaminathan S, Slim J, Chin B, De Wit S, Ali SM, Soriano Viladomiu A, Robinson P, Gottlieb RL, Tsang TYO, Lee IH, Haubrich RH, Chokkalingam AP, Lin L, Zhong L, Bekele BN, Mera-Giler R, Gallant J, Smith LE, Osinusi AO, Brainard DM, Hu H, Phulpin C, Edgar H, Diaz-Cuervo H, Bernardino JI. 2020. Remdesivir for Severe COVID-19 versus a Cohort Receiving Standard of Care. *Clin Infect Dis*. 2020 Jul 24:ciaa1041. doi: 10.1093/cid/ciaa1041. Epub ahead of print.

¹¹ WHO Solidarity Trial Consortium, Pan H, Peto R, Henaó-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Abdool Karim Q, Alejandria MM, Hernández García C, Kieny MP, Malekzadeh R, Murthy S, Reddy KS, Roses Periago M, Abi Hanna P, Ader F, Al-Bader AM, Alhasawi A, Allum E, Alotaibi A, Alvarez-Moreno CA, Appadoo S, Asiri A, Aukrust P, Barratt-Due A, Bellani S, Branca M, Cappel-Porter HBC, Cerrato N, Chow TS, Como N, Eustace J, García PJ, Godbole S, Gotuzzo E, Griskevicius L, Hamra R, Hassan M, Hassany M, Hutton D, Irmansyah I, Jancoriene L, Kirwan J, Kumar S, Lennon P, Lopardo G, Lydon P, Magrini N, Maguire T, Manevska S, Manuel O, McGinty S, Medina MT, Mesa Rubio ML, Miranda-Montoya MC, Nel J, Nunes EP, Perola M, Portolés A, Rasmin MR, Raza A, Rees H, Reges PPS, Rogers CA, Salami K, Salvadori MI, Sinani N, Sterne JAC, Stevanovikj M, Tacconelli E, Tikkinen KAO, Trelle S, Zaid H, Røttingen JA, Swaminathan S. 2021. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. *N Engl J Med*. 384:497-511.

¹² Al-Abdoun A, Bizanti A, Barbarawi M, Jabri A, Kumar A, Fashanu OE, Khan SU, Zhao D, Antar AAR, Michos ED. 2021. Remdesivir for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials. *Contemp Clin Trials*. 101:106272.

¹³ Wilt TJ, Kaka AS, MacDonald R, Greer N, Obley A, Duan-Porter W. 2021. Remdesivir for Adults With COVID-19 : A Living Systematic Review for American College of Physicians Practice Points. *Ann Intern Med*. 174:209-220.

¹⁴ Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, Hu Y, Luo G, Wang K, Lu Y, Li H, Wang S, Ruan S, Yang C, Mei C, Wang Y, Ding D, Wu F, Tang X, Ye X, Ye Y, Liu B, Yang J, Yin W, Wang A, Fan G, Zhou F, Liu Z, Gu X, Xu J, Shang L, Zhang Y, Cao L, Guo T, Wan Y, Qin H, Jiang Y, Jaki T, Hayden FG, Horby PW, Cao B, Wang C. 2020. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. *Lancet*. 395:1569-1578. Erratum in: *Lancet*. 395:1694.

¹⁵ Spinner CD, Gottlieb RL, Criner GJ, Arribas López JR, Cattelan AM, Soriano Viladomiu A, Ogbuagu O, Malhotra P, Mullane KM, Castagna A, Chai LYA, Roestenberg M, Tsang OTY, Bernasconi E, Le Turnier P, Chang SC, SenGupta D, Hyland RH, Osinusi AO, Cao H, Blair C, Wang H, Gaggar A, Brainard DM, McPhail MJ, Bhagani S, Ahn MY, Sanyal AJ, Huhn G, Marty FM; GS-US-540-5774 Investigators. 2020. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. *JAMA*. 324:1048-1057.

¹⁶ Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, Marconi VC, Ruiz-Palacios GM, Hsieh L, Kline S, Tapson V, Iovine NM, Jain MK, Sweeney DA, El Sahly HM, Branche AR, Regalado Pineda J, Lye DC, Sandkovsky U, Luetkemeyer AF, Cohen SH, Finberg RW, Jackson PEH, Taiwo B, Paules CI, Arguinchona H, Erdmann N, Ahuja N, Frank M, Oh MD, Kim ES, Tan SY, Mularski RA, Nielsen H, Ponce PO, Taylor BS, Larson L, Roupheal NG, Saklawi Y, Cantos VD, Ko ER, Engemann JJ, Amin AN, Watanabe M, Billings J, Elie MC, Davey RT, Burgess TH, Ferreira J, Green M, Makowski M, Cardoso A, de Bono S, Bonnett T, Proschan M, Deye GA, Dempsey W, Nayak SU, Dodd LE, Beigel JH; ACTT-2 Study Group Members. 2021. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. *N Engl J Med*. 384:795-807.

¹⁷ ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS. Acute respiratory distress syndrome: the Berlin Definition. 2012. *JAMA*. 307:2526-33.

¹⁸ Rajendram P, Sacha GL, Mehkri O, Wang X, Han X, Vachharajani V, Duggal A. 2021. Tocilizumab in Coronavirus Disease 2019-Related Critical Illness: A Propensity Matched Analysis. *Crit Care Explor.* 3:e0327